Julie E. Ledgerwood is an American allergist and immunologist, who is the chief medical officer and chief of the Clinical Trials Program at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in Bethesda, Maryland.

[1] Ledgerwood leads clinical trials and clinical collaborations for the VRC; and has served as principal investigator, protocol chair, or associate investigator for over 60 Phase 1-2b clinical trials studying vaccines and monoclonal antibodies targeting pathogens such as HIV, influenza, Ebola, malaria, Chikungunya, and Zika in over 13 countries.

Ledgerwood graduated from Phillips University in Enid, Oklahoma and received her Doctor of Osteopathic Medicine degree from the College of Osteopathic Medicine at Oklahoma State University Center for Health Sciences.

In 2002, Ledgerwood joined NIAID as a clinical fellow in allergy and immunology.

[1] Her work has been covered extensively in lay and scientific media outlets, including NBC News, Politico,[3] The Guardian,[4] NPR,[5] and The New York Times.